EX-99.1 11 exhibit9911231201610-k.htm EXHIBIT 99.1
Exhibit 99.1

FIVE-YEAR SUMMARY |  |  |  |  |  |  |  |  |  |
(In Thousands, Except for Per Share Amounts and Footnote Data)
Year Ended December 31 |  | 2016(a) |  | 2015(a)(b) |  | 2014 |  | 2013 |  | 2012
Results of Operations |  |  |  |  |  |  |  |  |  |
Net sales |  | $ | 2,677,203 |  |  | $ | 2,826,429 |  |  | $ | 2,445,548 |  |  | $ | 2,394,270 |  |  | $ | 2,519,154 |
Costs and expenses(c) |  | 2,102,652 |  |  | 2,481,318 |  |  | 2,174,250 |  |  | 1,817,595 |  |  | 2,119,371 |
Operating profit |  | 574,551 |  |  | 345,111 |  |  | 271,298 |  |  | 576,675 |  |  | 399,783 |
Interest and financing expenses |  | (65,181 | ) |  | (81,650 | ) |  | (41,358 | ) |  | (31,559 | ) |  | (32,800 | )
Other income (expenses), net |  | 5,894 |  |  | 47,283 |  |  | (16,761 | ) |  | (6,674 | ) |  | 1,229 |
Income from continuing operations before income taxes and equity in net income of unconsolidated investments |  | 515,264 |  |  | 310,744 |  |  | 213,179 |  |  | 538,442 |  |  | 368,212 |
Income tax expense |  | 96,263 |  |  | 11,134 |  |  | 18,484 |  |  | 134,445 |  |  | 80,433 |
Income from continuing operations before equity in net income of unconsolidated investments |  | 419,001 |  |  | 299,610 |  |  | 194,695 |  |  | 403,997 |  |  | 287,779 |
Equity in net income of unconsolidated investments (net of tax) |  | 59,637 |  |  | 27,978 |  |  | 35,742 |  |  | 31,729 |  |  | 38,067 |
Net income from continuing operations |  | 478,638 |  |  | 327,588 |  |  | 230,437 |  |  | 435,726 |  |  | 325,846 |
Income (loss) from discontinued operations (net of tax)(d) |  | 202,131 |  |  | 32,476 |  |  | (69,531 | ) |  | 4,108 |  |  | 4,281 |
Net income |  | 680,769 |  |  | 360,064 |  |  | 160,906 |  |  | 439,834 |  |  | 330,127 |
Net income attributable to noncontrolling interests |  | (37,094 | ) |  | (25,158 | ) |  | (27,590 | ) |  | (26,663 | ) |  | (18,591 | )
Net income attributable to Albemarle Corporation |  | $ | 643,675 |  |  | $ | 334,906 |  |  | $ | 133,316 |  |  | $ | 413,171 |  |  | $ | 311,536 |
Financial Position and Other Data |  |  |  |  |  |  |  |  |  |
Total assets(e) |  | $ | 8,161,207 |  |  | $ | 9,597,954 |  |  | $ | 5,202,437 |  |  | $ | 3,582,448 |  |  | $ | 3,434,340 |
Operations: |  |  |  |  |  |  |  |  |  |
Working capital |  | $ | 2,166,515 |  |  | $ | 214,317 |  |  | $ | 2,208,964 |  |  | $ | 1,046,552 |  |  | $ | 1,022,304 |
Current ratio |  | 2.90 |  |  | 1.13 |  |  | 2.94 |  |  | 3.40 |  |  | 3.66 |
Depreciation and amortization |  | $ | 226,169 |  |  | $ | 260,076 |  |  | $ | 103,572 |  |  | $ | 107,370 |  |  | $ | 99,020 |
Capital expenditures |  | $ | 196,654 |  |  | $ | 227,649 |  |  | $ | 110,576 |  |  | $ | 155,346 |  |  | $ | 280,873 |
Acquisitions, net of cash acquired |  | $ | 208,734 |  |  | $ | 2,100,490 |  |  | $ | — |  |  | $ | 2,565 |  |  | $ | 3,360 |
Cash proceeds from divestitures, net |  | $ | 3,325,571 |  |  | $ | 8,883 |  |  | $ | 104,718 |  |  | $ | — |  |  | $ | 9,646 |
Research and development expenses |  | $ | 80,475 |  |  | $ | 89,187 |  |  | $ | 88,310 |  |  | $ | 82,246 |  |  | $ | 78,919 |
Gross profit as a % of net sales |  | 36.3 |  |  | 30.4 |  |  | 31.5 |  |  | 35.5 |  |  | 35.7 |
Total long-term debt(e) |  | $ | 2,369,262 |  |  | $ | 3,817,157 |  |  | $ | 2,913,465 |  |  | $ | 1,076,515 |  |  | $ | 696,337 |
Total equity(f) |  | $ | 3,942,604 |  |  | $ | 3,401,313 |  |  | $ | 1,488,635 |  |  | $ | 1,742,776 |  |  | $ | 1,932,008 |
Total long-term debt as a % of total capitalization |  | 37.5 |  |  | 52.9 |  |  | 66.2 |  |  | 38.2 |  |  | 26.5 |
Net debt as a % of total capitalization(g) |  | 2.5 |  |  | 51.4 |  |  | 22.2 |  |  | 25.6 |  |  | 10.2 |
Common Stock |  |  |  |  |  |  |  |  |  |
Basic earnings (loss) per share |  |  |  |  |  |  |  |  |  |
Continuing operations |  | $ | 3.93 |  |  | $ | 2.72 |  |  | $ | 2.57 |  |  | $ | 4.88 |  |  | $ | 3.44 |
Discontinued operations |  | $ | 1.80 |  |  | $ | 0.29 |  |  | $ | (0.88 | ) |  | $ | 0.05 |  |  | $ | 0.05 |

Shares used to compute basic earnings per share |  | 112,379 |  |  | 111,182 |  |  | 78,696 |  |  | 83,839 |  |  | 89,189 |
Diluted earnings (loss) per share |  |  |  |  |  |  |  |  |  |
Continuing operations |  | $ | 3.90 |  |  | $ | 2.71 |  |  | $ | 2.57 |  |  | $ | 4.85 |  |  | $ | 3.42 |
Discontinued operations |  | $ | 1.78 |  |  | $ | 0.29 |  |  | $ | (0.88 | ) |  | $ | 0.05 |  |  | $ | 0.05 |
Shares used to compute diluted earnings per share |  | 113,239 |  |  | 111,556 |  |  | 79,102 |  |  | 84,322 |  |  | 89,884 |
Cash dividends declared per share |  | $ | 1.22 |  |  | $ | 1.16 |  |  | $ | 1.10 |  |  | $ | 0.96 |  |  | $ | 0.80 |
Total equity per share(f) |  | $ | 35.04 |  |  | $ | 30.31 |  |  | $ | 19.08 |  |  | $ | 21.77 |  |  | $ | 21.73 |
Return on average total equity |  | 17.5 | % |  | 13.7 | % |  | 8.3 | % |  | 22.5 | % |  | 17.3 | %

Footnotes:

(a) | On December 14, 2016 the Company sold the Chemetall Surface Treatment business, which qualifies for discontinued operations treatment because it represents a strategic shift that will have a major effect on the Company’s operations and financial results. As a result, in the second quarter of 2016, the Company began accounting for this business as discontinued operations in the consolidated statements of income and excluded the business from segment results for the years ended December 31, 2016 and 2015, the periods this business was owned by Albemarle. Related assets and liabilities are classified as held for sale for 2016 and 2015.

(b) | On January 12, 2015, we completed the acquisition of Rockwood Holdings, Inc. (“Rockwood”). Results for 2015 include the operations of Rockwood commencing on January 13, 2015.

(c) | The year ended December 31, 2016 included gains before income taxes of $11.5 million and $112.3 million related to the sales of the metal sulfides business and the minerals-based flame retardants and specialty chemicals business, respectively.

(d) | Included in Income (loss) from discontinued operations (net of tax) for the year ended December 31, 2016 is a pre-tax gain of $388.0 million ($135.0 million after income taxes) related to the sale of the Chemetall Surface Treatment business. T he year ended December 31, 2014 includes a pre-tax loss of $85.5 million ($65.7 million after income taxes) related to the sale of the antioxidant, ibuprofen and propofol businesses.

(e) | As a result of the adoption of new accounting guidance effective January 1, 2016 on a retrospective basis, unamortized debt issuance costs are now deducted from the carrying amount of the associated debt liability on the balance sheet. The reclassification of these unamortized debt issuance costs resulted in reductions of Long-term debt and Other assets on the consolidated balance sheets of $17.1 million in 2015, $20.6 million in 2014, $2.3 million in 2013 and $2.9 million in 2012.

(f) | Equity reflects the repurchase of common shares amounting to: 2016—0; 2015—0; 2014—2,190,254; 2013—9,198,056; and 2012—1,092,767. 2015 also includes the impact of 34,113,064 shares of common stock issued in connection with the acquisition of Rockwood.

(g) | We define net debt as total debt plus the portion of outstanding joint venture indebtedness guaranteed by us (or less the portion of outstanding joint venture indebtedness consolidated but not guaranteed by us), less cash and cash equivalents.